tirzepatide glp1 and gip Tirzepatide's Unique Mechanism of Action - GIP/GLP-1 Dual Agonist Understand GLP-1/GIP Dual Agonist Tirzepatide

The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites

C., Baker, N

Donne e infiammazione: attenzione alla salute riproduttiva Un altro punto critico rappresentato dalla salute femminile

Limit Triggers Like Caffeine and Alcohol Both can worsen dehydration and interact with blood sugar regulation

For weekly injections, alternate between different body areas each week